Sarcopenia Therapeutics Pipeline Marked by Positive Clinical Trial Results: P&S Market Research

NEW YORK, March 26, 2018 -- According to a new research report titled “Sarcopenia Therapeutics Pipeline Analysis 2018” published by P&S Market Research, Sarcopenia therapeutics currently exhibits a growing pipeline with 13 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis/report-sample

The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy.

Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.

The drugs being developed by the various pharmaceutical companies for the treatment of sarcopenia have demonstrated positive clinical trial results which in-turn aids in their further development. For instance, In June 2017, Novartis AG announced the positive results of a 24-week randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. In February 2016, ATA 842 demonstrated increased muscle mass and muscle strength in the treatment of young and old mice in four weeks.

Browse Full Report with detailed TOC on “Sarcopenia Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis

It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.

Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS and Vibe Pharmaceuticals LLC.

More Reports Published by P&S Market Research

Myelofibrosis Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis

CDK Inhibitors Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook